| Pair Name | Luteolin, Lapatinib | ||
| Phytochemical Name | Luteolin (PubChem CID: 5280445 ) | ||
| Anticancer drug Name | Lapatinib (PubChem CID: 208908 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Luteolin, Lapatinib | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Gene Regulation | Up-regulation | Expression | BCL2L11 | KEGG ID N.A. |
| Up-regulation | Expression | CDKN1A | hsa1026 | |
| Up-regulation | Expression | FOXO3 | hsa2309 | |
| Down-regulation | Phosphorylation | FOXO3 | hsa2309 | |
| Up-regulation | Expression | GADD45A | hsa1647 | |
| Up-regulation | Expression | NQO1 | hsa1728 | |
| In Vitro Model | SK-BR-3 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0033 |
| BT-474 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0179 | |
| ZR-75-1 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0588 | |
| In Vivo Model | Mice were inoculated subcutaneously with 0.1 mL of cell suspension (ZR-75-1 and BT-474 cells). | |||
| Result | These data suggest that the combination of Lapatinib and luteolin may inhibit HER2 human breast cancer by significantly increasing the expression of FOXO3a and NQO1, two key genes in HER2 human breast cancer xenografts. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Combination of Lapatinib and luteolin enhances the therapeutic efficacy of Lapatinib on human breast cancer through the FOXO3a/NQO1 pathway. Biochem Biophys Res Commun. 2020 Oct 20;531(3):364-371. doi: 10.1016/j.bbrc.2020.07.049. | Click |
